FourThought Financial’s CRISPR Therapeutics CRSP Stock Holding History

FourThought Financial’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$11K	Hold	164	–	–	﹤0.01%	1011
2022 Q2	$10K	Sell	164 -65	-28%	-$3.82K	﹤0.01%	1020
2022 Q1	$14K	Hold	229	–	–	﹤0.01%	980
2021 Q4	$17K	Buy	229 +103	+82%	+$9K	﹤0.01%	955
2021 Q3	$14K	Buy	126 +100	+385%	+$12.6K	﹤0.01%	1025
2021 Q2	$4K	Buy	26 +4	+18%	+$486	﹤0.01%	1244
2021 Q1	$2K	Hold	22	–	–	﹤0.01%	1299
2020 Q4	$3K	Buy	+22	New	+$2.6K	﹤0.01%	1214

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FourThought Financial's CRSP Position: Q3 2022 in Review

FourThought Financial held its CRISPR Therapeutics (CRSP) position steady in Q3 2022 at 164 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #1011.

FourThought Financial first reported a position in CRSP in Q4 2020 and has held it in 8 quarters since. The position peaked at $17K in Q4 2021. 436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

FourThought Financial held 164 shares of CRISPR Therapeutics worth $11K as of Q3 2022.
FourThought Financial left its CRISPR Therapeutics share count unchanged in Q3 2022.
CRISPR Therapeutics made up ﹤0.01% of FourThought Financial's portfolio in Q3 2022, its #1011 holding.
FourThought Financial first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 8 quarters since.
FourThought Financial's CRISPR Therapeutics position peaked at $17K in Q4 2021.
436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.